drugset / Trial / NCT04210713

Neuroimmune Dysfunction in Alcohol Use Disorder

NCT04210713

RandomizedParallel-groupTriple-blindTreatment

Summary

The objective of this proposal is to advance medication development for alcohol use disorder by examining the efficacy and mechanisms of action of minocycline, a neuroimmune modulator, as a potential treatment. This study has important clinical implications, as the available treatments for alcohol use disorder are only modestly effective and testing novel medications is a high research priority.

Timeline

Start
2020-02-03
Primary completion
2023-09-20
Completion
2023-09-20

Drugs

EvaluationDrugModalityDoseRoute
Comparator Minocycline Small molecule 200 mg